Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-9451 and Tegobuvir with PEG/RBV in Treatment-Naïve Genotype 1 HCV
NCT01271790Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2010
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of vedroprevir, tegobuvir in hepatitis C (HCV), sponsored by Gilead Sciences. Started Oct 2010; status: completed.
02
Drugs
vedroprevirtegobuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01271790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01271790.